Evidence map›Paper›PMID 41870981›Full record

ArticleMolecular oncology2026

Somatic mutational landscape in von Hippel-Lindau familial hemangioblastoma.

Maja Dembic, Anne Nørremølle, Lilian Bomme Ousager, Lars van Brakel Andersen, Marie Louise Mølgaard Binderup, Mads Thomassen

Abstract read
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maja DembicClinical Genome Center, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0000-0003-2505-6863
Anne NørremølleDepartment of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
Lilian Bomme OusagerClinical Genome Center, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Lars van Brakel AndersenClinical Genome Center, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Marie Louise Mølgaard BinderupDepartment of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
Mads ThomassenClinical Genome Center, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Funding

Harboefonden 17143Jacob og Olga Madsens Fond 3664Læge Sofus Carl Emil og Hustru Olga Doris Friis' Legat
6 · The paper itself

Abstract

Von Hippel-Lindau disease (vHL) predisposes to tumor development, mainly clear cell renal carcinoma and hemangioblastoma. The underlying cause is germline variants in the VHL gene, with tumorigenesis thought to require additional somatic 'second-hit' events that most commonly include loss of 3p. However, the precise mechanisms of vHL-related tumor development remain incompletely understood. Genomic investigations of familial hemangioblastoma may help elucidate the early steps of tumorigenesis and contribute to improved disease prediction, biomarker discovery, and therapeutic strategies. We performed whole exome sequencing on 22 familial hemangioblastomas from 7 patients representing 5 unrelated families, and with 4 different causative VHL genotypes. The tumors exhibited low overall mutational burden but showed frequent loss of heterozygosity on chromosome 3 or 3p and single nucleotide variants in the VHL region. Variants were significantly enriched in genes associated with GABAergic and serotonergic neuronal cell types, as well as in pathways regulating cell cycle and neurogenesis. These findings suggest that, in addition to VHL loss, dysregulation of neuronal differentiation programs and cell cycle control may play important roles in hemangioblastoma tumorigenesis.

Indexed as

HemangioblastomaMutationvon Hippel-Lindau DiseaseVon Hippel-Lindau Tumor Suppressor ProteinAdultFemaleHumansLoss of HeterozygosityMalePedigreePolymorphism, Single NucleotideVHL protein, humanVon Hippel-Lindau Tumor Suppressor Proteincopy numberhemangioblastomasingle nucleotidesomaticVHLWES

Identifiers

PMID41870981
PMCPMC13398559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.